Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted regulatory approval for a label expansion of KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor for the treatment of people with cystic fibrosis (CF). With this approval, the indication has been expanded to include all patients ages 2 years and older who have at least one non-class I mutation in the cystic fibrosis conductance regulator (CFTR) gene. “We have been work...

Today, Wine Institute released the following statement from President and CEO Robert P. Koch in response to the administration’s announcement of new reciprocal tariffs affecting numerous trade partners, including those involved in the import and export of wine with the United States. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250407422670/en/“This isn’t just about trade. It’s about people, livelihoods and an agricultural success ...